US2951540A
(en)
|
1956-11-05 |
1960-09-06 |
Gen Motors Corp |
Propeller brake
|
US3709898A
(en)
|
1971-02-09 |
1973-01-09 |
Upjohn Co |
Process for the production of triazolobenzodiazepines and intermediates
|
US3681343A
(en)
|
1971-05-11 |
1972-08-01 |
Upjohn Co |
6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
|
US3812259A
(en)
|
1971-08-09 |
1974-05-21 |
Upjohn Co |
Animal feed and process
|
CH622019A5
(en)
|
1975-10-23 |
1981-03-13 |
Upjohn Co |
Process for the preparation of aminotriazolobenzodiazepines
|
FR2329668A1
(en)
|
1975-10-27 |
1977-05-27 |
Upjohn Co |
Sedative, tranquillising, antidepressant triazolo-benzodiazepines - prepn. from hydrazino-benzodiazepines
|
EP0087850A1
(en)
|
1982-01-04 |
1983-09-07 |
The Upjohn Company |
Benzodiazepines for anti-hypertensive use
|
DE3435973A1
(en)
|
1984-10-01 |
1986-04-10 |
Boehringer Ingelheim KG, 6507 Ingelheim |
PHARMACEUTICAL COMPOSITIONS CONTAINING DIAZEPINE WITH PAF-ANTAGONISTIC EFFECT
|
DE3724164A1
(en)
|
1986-07-25 |
1988-01-28 |
Boehringer Ingelheim Kg |
Novel 1,4-benzodiazepines, their preparation and use
|
WO1988009333A1
(en)
|
1987-05-28 |
1988-12-01 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Thieno(triazolo)diazepine compound and medicinal application of the same
|
JPH0676326B2
(en)
|
1988-05-24 |
1994-09-28 |
吉富製薬株式会社 |
Cardiovascular drug
|
EP0368175A1
(en)
|
1988-11-06 |
1990-05-16 |
Boehringer Ingelheim Kg |
3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine.
|
EP0387613A1
(en)
|
1989-03-03 |
1990-09-19 |
Boehringer Ingelheim Kg |
Thienodiazepines
|
CA2020806A1
(en)
|
1989-07-12 |
1991-01-13 |
Karl-Heinz Weber |
Thienodiazepine derivatives
|
DE4010528A1
(en)
|
1990-04-02 |
1991-10-17 |
Boehringer Ingelheim Kg |
PRECARATIVE CHROMATOGRAPHIC SEPARATION METHOD FOR THE PRODUCTION OF ENANTIOMERALLY PURE HETRAZEPINE
|
US5593988A
(en)
|
1991-10-11 |
1997-01-14 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Therapeutic agent for osteoporosis and diazepine compound
|
WO1994006802A1
(en)
|
1992-09-18 |
1994-03-31 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Thienodiazepine compound and medicinal use thereof
|
WO1994022872A1
(en)
|
1993-03-30 |
1994-10-13 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Cell adhesion inhibitor and thienotriazolodiazepine compound
|
WO1995032963A1
(en)
|
1994-06-01 |
1995-12-07 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Thienylazole compound and thienotriazolodiazepine compound
|
JP3001979B2
(en)
|
1995-01-06 |
2000-01-24 |
エフ・ホフマン−ラ ロシュ アーゲー |
Hydroxymethyl-imidazodiazepines and their esters
|
US5730723A
(en)
|
1995-10-10 |
1998-03-24 |
Visionary Medical Products Corporation, Inc. |
Gas pressured needle-less injection device and method
|
WO1996039384A1
(en)
*
|
1995-06-06 |
1996-12-12 |
Pfizer, Inc. |
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
|
JP3068200B2
(en)
*
|
1995-06-06 |
2000-07-24 |
ファイザー・インコーポレーテッド |
Substituted N- (indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
|
CN1101680C
(en)
|
1995-09-09 |
2003-02-19 |
弗·哈夫曼-拉罗切有限公司 |
Use of thienotriazolodiazepine to increase apolipoprotein A-I levels
|
GB9607549D0
(en)
|
1996-04-11 |
1996-06-12 |
Weston Medical Ltd |
Spring-powered dispensing device
|
CA2258053A1
(en)
|
1996-06-12 |
1997-12-18 |
Yoshihisa Yamamoto |
Cytokine production inhibitors, triazepine compounds, and intermediates thereof
|
US5693641A
(en)
|
1996-08-16 |
1997-12-02 |
Berlex Laboratories Inc. |
Bicyclic pyrimidine derivatives and their use as anti-coagulants
|
WO1998011111A1
(en)
|
1996-09-13 |
1998-03-19 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Thienotriazolodiazepine compounds and medicinal uses thereof
|
US6444664B1
(en)
|
1997-04-18 |
2002-09-03 |
Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) |
Method for controlling the plasma level of lipoproteins to treat alzheimeris disease
|
JPH11228576A
(en)
|
1997-12-10 |
1999-08-24 |
Japan Tobacco Inc |
Apoptosis inhibitor
|
IT1298087B1
(en)
|
1998-01-08 |
1999-12-20 |
Fiderm S R L |
DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
|
FR2779652B1
(en)
|
1998-06-15 |
2001-06-08 |
Sod Conseils Rech Applic |
USE OF DIAZEPINES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CONDITIONS OR DISEASES IN WHICH ONE OF THE SOMATOSTATIN RECEPTORS IS INVOLVED
|
KR20000016732A
(en)
|
1998-12-12 |
2000-03-25 |
Japan Tobacco Inc |
Cytokine production inhibitors, triazepine compounds, and intermediates thereof
|
JP2003520195A
(en)
|
1999-05-14 |
2003-07-02 |
イムクローン システムズ インコーポレイティド |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
US6312215B1
(en)
|
2000-02-15 |
2001-11-06 |
United Technologies Corporation |
Turbine engine windmilling brake
|
US7589167B2
(en)
|
2000-02-22 |
2009-09-15 |
J. David Gladstone Institutes |
ZA loops of bromodomains
|
AU2001264303A1
(en)
|
2000-06-16 |
2001-12-24 |
Mitsubishi Pharma Corporation |
Compositions controlling release ph range and/or speed
|
WO2002002557A2
(en)
|
2000-06-30 |
2002-01-10 |
Neurogen Corporation |
2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
|
US20060142257A1
(en)
|
2001-01-19 |
2006-06-29 |
Eberhard Nieschlag |
Male contraceptive formulation comprising norethisterone
|
US6979682B2
(en)
|
2001-02-23 |
2005-12-27 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast
|
US20030216758A1
(en)
|
2001-12-28 |
2003-11-20 |
Angiotech Pharmaceuticals, Inc. |
Coated surgical patches
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
PL378116A1
(en)
|
2003-02-27 |
2006-03-06 |
Abbott Laboratories |
Heterocyclic kinase inhibitors
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
WO2005000335A2
(en)
*
|
2003-06-02 |
2005-01-06 |
Ohio University |
Use of genes differentially expressed during aging of liver for treatment and diagnosis
|
WO2005002526A2
(en)
|
2003-07-01 |
2005-01-13 |
President And Fellows Of Harvard College |
Method and compositions for treatment of viral infections
|
AU2004272288B2
(en)
|
2003-09-18 |
2008-11-13 |
Novartis Ag |
2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
|
EP1528056A1
(en)
|
2003-10-29 |
2005-05-04 |
Academisch Ziekenhuis bij de Universiteit van Amsterdam |
Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
CN1759834B
(en)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat
|
US8624027B2
(en)
|
2005-05-12 |
2014-01-07 |
Abbvie Inc. |
Combination therapy for treating cancer and diagnostic assays for use therein
|
WO2006129623A1
(en)
*
|
2005-05-30 |
2006-12-07 |
Mitsubishi Tanabe Pharma Corporation |
Thienotriazolodiazepine compound and a medicinal use thereof
|
JP2009503014A
(en)
|
2005-08-03 |
2009-01-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dihydropteridinone in the treatment of respiratory diseases
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
PT1951684T
(en)
|
2005-11-01 |
2016-10-13 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
US20070105887A1
(en)
|
2005-11-04 |
2007-05-10 |
Wyeth |
Antineoplastic combinations of temsirolimus and sunitinib malate
|
SI1962830T1
(en)
|
2005-12-23 |
2013-07-31 |
Glaxosmithkline Llc |
Azaindole inhibitors of aurora kinases
|
EP1979350A1
(en)
|
2006-01-17 |
2008-10-15 |
F.Hoffmann-La Roche Ag |
Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors
|
NZ570530A
(en)
|
2006-02-14 |
2011-09-30 |
Vertex Pharma |
Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
|
US20070218135A1
(en)
|
2006-03-14 |
2007-09-20 |
Glenmark Pharmaceuticals Limited |
Sustained release matrix pharmaceutical composition
|
US20090281191A1
(en)
|
2006-05-03 |
2009-11-12 |
Rangwala Shamina M |
Use of organic compounds
|
US7621117B2
(en)
|
2006-06-19 |
2009-11-24 |
Pratt & Whitney Canada Corp. |
Apparatus and method for controlling engine windmilling
|
EP2078016B1
(en)
|
2006-10-19 |
2012-02-01 |
Signal Pharmaceuticals LLC |
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
|
US8338464B2
(en)
|
2006-11-30 |
2012-12-25 |
Albert Einstein College Of Medicine Of Yeshiva University |
Small molecule inhibitors of BCL6
|
KR101810348B1
(en)
|
2006-12-26 |
2017-12-18 |
랜티우스 메디컬 이메징, 인크. |
Ligands for imaging cardiac innervation
|
JP2008156311A
(en)
|
2006-12-26 |
2008-07-10 |
Institute Of Physical & Chemical Research |
Brd2 bromodomain binder
|
WO2008137081A1
(en)
|
2007-05-02 |
2008-11-13 |
The Trustees Of Columbia University In The City Of New York |
Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives
|
KR20080107050A
(en)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
Pharmaceutical composition for preventing or treating chronic graft-versus-host disease comprising anti-cd137 monoclonal antibody
|
US20110028405A1
(en)
|
2007-12-20 |
2011-02-03 |
Richard John Harrison |
Sulfamides as zap-70 inhibitors
|
WO2009084693A1
(en)
|
2007-12-28 |
2009-07-09 |
Mitsubishi Tanabe Pharma Corporation |
Antitumor agent
|
US8014061B2
(en)
*
|
2007-12-28 |
2011-09-06 |
Nippon Telegraph And Telephone Corporation |
Variable-focal length lens
|
US20110098288A1
(en)
|
2008-03-11 |
2011-04-28 |
Jeremy Major |
Sulfonamides as zap-70 inhibitors
|
WO2010015340A1
(en)
|
2008-08-06 |
2010-02-11 |
Bayer Schering Pharma Aktiengesellschaft |
Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
|
CN102292341B
(en)
|
2008-10-30 |
2014-09-10 |
环行医学有限责任公司 |
Thienotriazolodiazepine derivatives active on APO A
|
CA2748181C
(en)
|
2009-01-06 |
2019-07-16 |
Nathanael S. Gray |
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
|
WO2010085570A1
(en)
|
2009-01-23 |
2010-07-29 |
Takeda Pharmaceutical Company Limited |
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
|
GB0919431D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919423D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919434D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
GB0919426D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
KR20120097508A
(en)
|
2009-11-05 |
2012-09-04 |
글락소스미스클라인 엘엘씨 |
Benzodiazepine bromodomain inhibitor
|
GB0919432D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Use
|
MX2012005295A
(en)
|
2009-11-05 |
2012-06-19 |
Glaxosmithkline Llc |
Benzodiazepine bromodomain inhibitor.
|
US8862173B2
(en)
|
2009-12-10 |
2014-10-14 |
Motorola Solutions, Inc. |
Method for selecting media for delivery to users at an incident
|
EP2536725B1
(en)
|
2010-02-17 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
Dihydropteridinones, method for production and use thereof
|
US9624870B2
(en)
|
2010-03-26 |
2017-04-18 |
Rolls-Royce North American Technologies, Inc. |
Adaptive fan system for a variable cycle turbofan engine
|
CN103154246B
(en)
|
2010-05-14 |
2015-11-25 |
达那-法伯癌症研究所 |
Be used for the treatment of leukemic composition and method
|
PL2902030T3
(en)
|
2010-05-14 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Thienotriazolodiazepine compounds for treating neoplasia
|
JP5715241B2
(en)
|
2010-05-14 |
2015-05-07 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders
|
EP2569429A4
(en)
*
|
2010-05-14 |
2013-09-25 |
Dana Farber Cancer Inst Inc |
Compositions and methods for modulating metabolism
|
CA2799381A1
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Male contraceptive compositions and methods of use
|
US9085582B2
(en)
|
2010-06-22 |
2015-07-21 |
Glaxosmithkline Llc |
Benzotriazolodiazepine compounds inhibitors of bromodomains
|
US9320711B2
(en)
|
2010-06-25 |
2016-04-26 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for CNS delivery of heparan N-sulfatase
|
US20120014979A1
(en)
|
2010-07-16 |
2012-01-19 |
Alexander Dent |
Use of bcl6 inhibitors for treating autoimmune diseases
|
TWI549955B
(en)
|
2010-08-04 |
2016-09-21 |
達納 法柏癌症學院有限公司 |
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
|
CN103228142A
(en)
*
|
2010-09-28 |
2013-07-31 |
加利福尼亚大学董事会 |
GABA agonists in treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
|
AR084070A1
(en)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
BROMODOMINIUM INHIBITORS AND USES OF THE SAME
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
US20130004481A1
(en)
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
CN103547152A
(en)
|
2011-02-23 |
2014-01-29 |
西奈山伊坎医学院 |
Inhibitors of bromodomains as modulators of gene expression
|
ES2951688T3
(en)
|
2011-02-28 |
2023-10-24 |
Epizyme Inc |
6,5-Substituted Fused Bicyclic Heteroaryl Compounds
|
WO2012119095A1
(en)
|
2011-03-02 |
2012-09-07 |
Board Of Regents, The University Of Texas System |
Fus1/tusc2 therapies
|
AU2012290261A1
(en)
|
2011-07-29 |
2014-02-20 |
The Children's Hospital Of Philadelphia |
Compositions and methods for the treatment of HIV
|
WO2013033269A1
(en)
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
WO2013033268A2
(en)
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bivalent bromodomain ligands, and methods of using same
|
FI20110279A0
(en)
|
2011-08-29 |
2011-08-29 |
Outotec Oyj |
A method for recovering metals from material containing them
|
US10071129B2
(en)
|
2011-08-30 |
2018-09-11 |
Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. |
Method for identifying bromodomain inhibitors
|
DE102011082013A1
(en)
|
2011-09-01 |
2013-03-07 |
Bayer Pharma AG |
6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepines
|
WO2013097052A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
JP2015508780A
(en)
|
2012-02-17 |
2015-03-23 |
アンサン バイオファーマ,インコーポレイテッド |
Methods, compounds, and compositions for treating influenza and parainfluenza viruses in immunocompromised patients
|
EP2830629A4
(en)
|
2012-03-28 |
2016-01-20 |
Icahn School Of Medicine Mount Sinai |
Compositions and methods for reactivating latent immunodeficiency virus
|
WO2013192274A2
(en)
|
2012-06-19 |
2013-12-27 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
RU2015115634A
(en)
|
2012-09-28 |
2016-11-20 |
Онкоэтикс Гмбх |
PHARMACEUTICAL COMPOSITION containing thienotriazolodiazepine compounds
|
US9567301B2
(en)
|
2012-11-02 |
2017-02-14 |
Dana-Farber Cancer Institute, Inc. |
Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors
|
US20160009725A1
(en)
|
2013-02-22 |
2016-01-14 |
Bayer Pharma Aktiengesellschaft |
Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
|
JP2016513118A
(en)
|
2013-02-22 |
2016-05-12 |
バイエル ファーマ アクチエンゲゼルシャフト |
4-substituted pyrrolo- and pyrazolodiazepines
|
CA2902225A1
(en)
|
2013-02-28 |
2014-09-04 |
Washington University |
Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
BR112015023184A2
(en)
|
2013-03-15 |
2017-11-21 |
Constellation Pharmaceuticals Inc |
method for treating a disease, inhibitor and its use, composition, method of identifying a compound and method for inhibiting the production of il-4, il-5 and il-13
|
EP3003312A1
(en)
|
2013-05-28 |
2016-04-13 |
Dana-Farber Cancer Institute, Inc. |
Bet inhibition therapy for heart disease
|
DE102013106353B4
(en)
|
2013-06-18 |
2018-06-28 |
Tdk Corporation |
Method for applying a structured coating to a component
|
WO2015013635A2
(en)
|
2013-07-25 |
2015-01-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
WO2015018522A1
(en)
|
2013-08-06 |
2015-02-12 |
Oncoethix Sa |
Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
|
US20160158246A1
(en)
|
2013-08-06 |
2016-06-09 |
Oncoethix Gmbh |
Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
|
US20160201063A1
(en)
|
2013-08-16 |
2016-07-14 |
Rana Therapeutics, Inc. |
Epigenetic regulators of frataxin
|
US8988212B2
(en)
|
2013-08-22 |
2015-03-24 |
GM Global Technology Operations LLC |
Electric vehicle pedestrian warning system
|
CA2922503C
(en)
|
2013-09-19 |
2021-10-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
WO2015054642A2
(en)
|
2013-10-11 |
2015-04-16 |
Genentech, Inc. |
Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
|
US11446309B2
(en)
|
2013-11-08 |
2022-09-20 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
|
WO2015081284A1
(en)
|
2013-11-26 |
2015-06-04 |
Coferon, Inc. |
Bivalent bromodomain ligands, and methods of using same
|
MX2016009974A
(en)
|
2014-01-31 |
2016-10-31 |
Dana Farber Cancer Inst Inc |
Diaminopyrimidine benzenesulfone derivatives and uses thereof.
|
BR112016017045A2
(en)
|
2014-01-31 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
DIAZEPANE DERIVATIVES AND USES THEREOF
|
WO2015117087A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
US10925881B2
(en)
|
2014-02-28 |
2021-02-23 |
Tensha Therapeutics, Inc. |
Treatment of conditions associated with hyperinsulinaemia
|
AU2015339511B2
(en)
|
2014-10-27 |
2020-05-14 |
Tensha Therapeutics, Inc. |
Bromodomain inhibitors
|
US10813939B2
(en)
|
2014-12-05 |
2020-10-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bromodomain inhibitor as adjuvant in cancer immunotherapy
|
BR112017028178A2
(en)
|
2015-06-26 |
2018-08-28 |
Tensha Therapeutics Inc |
nut midline carcinoma treatment
|
MA43037A
(en)
|
2015-10-02 |
2018-08-08 |
Dana Farber Cancer Inst Inc |
BROMODOMAIN INHIBITOR POLYTHERAPY AND CHECKPOINT BLOCKING
|